DayTwo, a microbiome human discovery platform with an actionable product in the market, received an investment from Longliv Ventures, a member of CK Hutchison Holdings Group, the global VC partnership Cathay Innovation, and Samsung NEXT as strategic investors and partners.
Longliv Ventures, Cathay Innovation and Samsung NEXT will participate in the company’s Series B financing, announced in June of this year. Longliv Ventures will invest $5m USD in this round and Dr. Dan Eldar, Managing Director at Longliv Ventures, will join the company’s board of directors.
Led by Lihi Segal, CEO and Founder, DayTwo provides a microbiome platform built upon a large full-shotgun database of gut-microbiome profiles worldwide.
The company, which has offices in Tel Aviv, Israel and San Francisco Bay Area, has a food-as-medicine approach based on the original research conducted by Professors Eran Segal, Ph.D., and Eran Elinav, M.D., Ph.D. at The Weizmann Institute of Science, published in the journal Cell, in 2015. The Cell paper demonstrates how the gut microbiome, in conjunction with other clinical and personal parameters, can enable personalized dietary interventions that can balance post-meal glucose response.
The company has 85 employees.